Factors Affecting Mydriasis-Free Flicker ERGs Recorded With Real-Time Correction for Retinal Illuminance: Study of 150 Young Healthy Subjects

Kato, Kumiko; Kondo, Mineo; Nagashima, Ryunosuke; Sugawara, Asako; Sugimoto, Masahiko; Matsubara, Hisashi; McCulloch, Daphne L.; Ikesugi, Kengo

doi:10.1167/iovs.17-22587

“…At 14 years of age, BCVA decreased to 0.05 in each eye. Electroretinography (ERG) with skin electrodes was performed using the RET eval system (LKC Technologies, Gaithersburg, MD) as previously described (Kato et al, 2017), which showed that the light‐adapted 30‐Hz flicker response was non‐recordable (Figure 1c). At this time, he was ophthalmologically diagnosed with progressive retinal dystrophy such as retinitis pigmentosa, in addition to optic disc atrophy.…”

Section: Resultsmentioning

confidence: 99%

Long‐term observation of a Japanese mucolipidosis IV patient with a novel homozygous p.F313del variant of MCOLN1

Hayashi

¹

,

Hosono

²

,

Kubo

³

et al. 2020

American J of Med Genetics Pt A

Self Cite

View full text Add to dashboard Cite

Mucolipidosis type IV (MLIV) is an autosomal recessively inherited lysosomal storage disorder characterized by progressive psychomotor delay and retinal degeneration that is associated with biallelic variants in the MCOLN1 gene. The gene, which is expressed in late endosomes and lysosomes of various tissue cells, encodes the transient receptor potential channel mucolipin 1 consisting of six transmembrane domains. Here, we described 14-year follow-up observation of a 4-year-old Japanese male MLIV patient with a novel homozygous in-frame deletion variant p.(F313del), which was identified by whole-exome sequencing analysis. Neurological examination revealed progressive psychomotor delay, and atrophy of the corpus callosum and cerebellum was observed on brain magnetic resonance images. Ophthalmologically, corneal clouding has remained unchanged during the follow-up period, whereas optic nerve pallor and retinal degenerative changes exhibited progressive disease courses. Light-adapted electroretinography was non-recordable. Transmission electron microscopy of granulocytes revealed characteristic concentric multiple lamellar structures and an electron-dense inclusion in lysosomes. The in-frame deletion variant was located within the second transmembrane domain, which is of putative functional importance for channel properties. K E Y W O R D S lysosomal storage disorder, MCOLN1, mucolipidosis type IV, psychomotor delay, retinal degeneration

show abstract

“…Flicker ERGs were recorded three times from both eyes with the RETeval® system (Mayo, Inazawa, Japan); the first recording was made before the injection of an anti-VEGF agent (Phase 1), the second was within 2 hours after the injection (Phase 2), and the third was 2 to 24 hours after the injection (Phase 3). The components of the RETeval system have been described in detail [21,24,25,27].…”

Section: Methodsmentioning

confidence: 99%

Retinal Function determined by Flicker ERGs before and soon after Intravitreal Injection of Anti-VEGF Agents

Terauchi

¹

,

Shinoda²,

Sakai

³

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: To evaluate the retinal function before and soon after an intravitreal injection of an anti-vascular endothelial growth factor (anti-VEGF) agents. Methods: Seventy-nine eyes of 79 patients that were treated by an intravitreal injection of an anti-VEGF agent for age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion (RVO) with macular edema (ME) were studied. The RETeval® system was used to record 28 Hz flicker electroretinograms (ERGs) from the injected and non-injected eyes before (Phase 1, P1), within 2 hours after the injection (P2), and 2 to 24 hours after the injection (P3). Patients were grouped by disease or by the injected agent and compared. The significance of the changes in the implicit times and amplitudes was determined by t tests. Results: The amplitudes were not significantly different at the three phases. The implicit time of the injected eye was 31.2±3.2 msec at P1, and it was not significantly different at P2 (31.7±3.1 msec) but it was significantly longer at P3 (32.2±3.3 msec, P<0.01, ANOVA for both). The implicit time in the non-injected fellow eye was 30.5±3.3 msec at P1, and it was significantly longer at P2 (31.1±3.2 msec) and phase 3 (31.3±3.4 msec, P<0.01, ANOVA for both). Conclusions: The results indicate that an intravitreal anti-VEGF injection will increase the implicit times not only in the injected eye but also in the non-injected eye soon after the intravitreal injection.

show abstract

“…Flicker ERGs were recorded three times from both eyes with the RETeval® system (Mayo, Inazawa, Japan); the first recording was made before the injection of an anti-VEGF agent (Phase 1), the second was within 2 hours after the injection (Phase 2), and the third was 2 to 24 hours after the injection (Phase 3). The components of the RETeval system have been described in detail [21,24,25,27]. recording.…”

Section: Methodsmentioning

confidence: 99%

Retinal Function determined by Flicker ERGs before and soon after Intravitreal Injection of Anti-VEGF Agents

Terauchi

¹

,

Shinoda²,

Sakai

³

et al. 2019

Preprint

0

View full text Add to dashboard Cite

Background: To evaluate the retinal function before and soon after an intravitreal injection of an anti-vascular endothelial growth factor (anti-VEGF) agents. Methods: Seventy-nine eyes of 79 patients that were treated by an intravitreal injection of an anti-VEGF agent for age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion (RVO) with macular edema (ME) were studied. The RETeval® system was used to record 28 Hz flicker electroretinograms (ERGs) from the injected and non-injected eyes before (Phase 1, P1), within 2 hours after the injection (P2), and 2 to 24 hours after the injection (P3). Patients were grouped by disease or by the injected agent and compared. The significance of the changes in the implicit times and amplitudes was determined by t tests. Results: The amplitudes were not significantly different at the three phases. The implicit time of the injected eye was 31.2±3.2 msec at P1, and it was not significantly different at P2 (31.7±3.1 msec) but it was significantly longer at P3 (32.2±3.3 msec, P<0.01, ANOVA for both). The implicit time in the non-injected fellow eye was 30.5±3.3 msec at P1, and it was significantly longer at P2 (31.1±3.2 msec) and phase 3 (31.3±3.4 msec, P<0.01, ANOVA for both). Conclusions: The results indicate that an intravitreal anti-VEGF injection will increase the implicit times not only in the injected eye but also in the non-injected eye soon after the intravitreal injection.

show abstract

Factors Affecting Mydriasis-Free Flicker ERGs Recorded With Real-Time Correction for Retinal Illuminance: Study of 150 Young Healthy Subjects

Cited by 24 publications

References 40 publications

Long‐term observation of a Japanese mucolipidosis IV patient with a novel homozygous p.F313del variant of MCOLN1

Long‐term observation of a Japanese mucolipidosis IV patient with a novel homozygous p.F313del variant of MCOLN1

Retinal Function determined by Flicker ERGs before and soon after Intravitreal Injection of Anti-VEGF Agents

Retinal Function determined by Flicker ERGs before and soon after Intravitreal Injection of Anti-VEGF Agents

Contact Info

Product

Resources

About